Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Subjective Complaints as Main Reason for Biosimilar Discontinuation after Open Label Transitioning from Originator to Biosimilar Infliximab.

Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, den Broeder AA.

Arthritis Rheumatol. 2017 Oct 18. doi: 10.1002/art.40324. [Epub ahead of print]

PMID:
29045077
2.

Development of the "Treatment beliefs in knee and hip OsteoArthritis (TOA)" questionnaire.

Selten EMH, Vriezekolk JE, Schers HJ, Nijhof MW, van der Laan WH, van der Meulen-Dilling RG, Geenen R, van den Ende CHM.

BMC Musculoskelet Disord. 2017 Sep 19;18(1):402. doi: 10.1186/s12891-017-1762-3.

3.

Barriers Impeding the Use of Non-pharmacological, Non-surgical Care in Hip and Knee Osteoarthritis: The Views of General Practitioners, Physical Therapists, and Medical Specialists.

Selten EMH, Vriezekolk JE, Nijhof MW, Schers HJ, van der Meulen-Dilling RG, van der Laan WH, Geenen R, van den Ende CHM.

J Clin Rheumatol. 2017 Sep 19. doi: 10.1097/RHU.0000000000000562. [Epub ahead of print]

PMID:
28926466
4.

Treatment Beliefs Underlying Intended Treatment Choices in Knee and Hip Osteoarthritis.

Selten EMH, Geenen R, Schers HJ, van den Hoogen FHJ, van der Meulen-Dilling RG, van der Laan WH, Nijhof MW, van den Ende CHM, Vriezekolk JE.

Int J Behav Med. 2017 Jun 29. doi: 10.1007/s12529-017-9671-2. [Epub ahead of print]

PMID:
28664420
5.

Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?

Pasma A, Schenk C, Timman R, van 't Spijker A, Appels C, van der Laan WH, van den Bemt B, Goekoop R, Hazes JM, Busschbach JJ.

PLoS One. 2017 Feb 2;12(2):e0171070. doi: 10.1371/journal.pone.0171070. eCollection 2017.

6.

Hierarchical structure and importance of patients' reasons for treatment choices in knee and hip osteoarthritis: a concept mapping study.

Selten EM, Geenen R, van der Laan WH, van der Meulen-Dilling RG, Schers HJ, Nijhof MW, van den Ende CH, Vriezekolk JE.

Rheumatology (Oxford). 2017 Feb;56(2):271-278. doi: 10.1093/rheumatology/kew409. Epub 2016 Nov 17.

PMID:
27864564
7.

Psychosocial predictors of DMARD adherence in the first three months of treatment for early arthritis.

Pasma A, Hazes JM, Busschbach JJ, van der Laan WH, Appels C, de Man YA, Nieboer D, Timman R, van 't Spijker A.

Patient Educ Couns. 2017 Jan;100(1):126-132. doi: 10.1016/j.pec.2016.07.019. Epub 2016 Jul 15.

PMID:
27516438
8.

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.

Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, Bernasconi C, Borm MEA, Wortel CH, Ter Borg EJ, Jahangier ZN, van der Laan WH, Bruyn GAW, Baudoin P, Wijngaarden S, Vos PAJM, Bos R, Starmans MJF, Griep EN, Griep-Wentink JRM, Allaart CF, Heurkens AHM, Teitsma XM, Tekstra J, Marijnissen ACA, Lafeber FPJ, Jacobs JWG.

Lancet. 2016 Jul 23;388(10042):343-355. doi: 10.1016/S0140-6736(16)30363-4. Epub 2016 Jun 7.

PMID:
27287832
9.

Cost of illness and illness perceptions in patients with fibromyalgia.

Vervoort VM, Vriezekolk JE, Olde Hartman TC, Cats HA, van Helmond T, van der Laan WH, Geenen R, van den Ende CH.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2 Suppl 96):S74-82. Epub 2016 Feb 8.

PMID:
26886404
10.

Reasons for Treatment Choices in Knee and Hip Osteoarthritis: A Qualitative Study.

Selten EM, Vriezekolk JE, Geenen R, van der Laan WH, van der Meulen-Dilling RG, Nijhof MW, Schers HJ, van den Ende CH.

Arthritis Care Res (Hoboken). 2016 Sep;68(9):1260-7. doi: 10.1002/acr.22841. Epub 2016 Jul 28.

11.

Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease.

Pasma A, Schenk CV, Timman R, Busschbach JJ, van den Bemt BJ, Molenaar E, van der Laan WH, Schrauwen S, Van't Spijker A, Hazes JM.

Arthritis Res Ther. 2015 Oct 8;17:281. doi: 10.1186/s13075-015-0801-4.

12.

Progression of joint damage despite control of inflammation in rheumatoid arthritis: a role for cartilage damage driven synovial fibroblast activity.

Lafeber FP, Van der Laan WH.

Ann Rheum Dis. 2012 Jun;71(6):793-5. doi: 10.1136/annrheumdis-2011-200950. No abstract available.

PMID:
22566404
13.

Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.

Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, Geurts MA, van der Werf JH, van Albada-Kuipers GA, Jahangier-de Veen ZN, van der Veen MJ, Verhoef CM, Lafeber FP, Bijlsma JW; Utrecht Rheumatoid Arthritis Cohort Study Group.

Ann Intern Med. 2012 Mar 6;156(5):329-39. doi: 10.7326/0003-4819-156-5-201203060-00004.

PMID:
22393128
14.

['Rheumatoid arthritis' in a Surinamese man: leprosy].

van der Laan WH, Faber WR, de Vries N, Maas M, Tak PP.

Ned Tijdschr Geneeskd. 2009;153:A246. Dutch.

PMID:
19785864
15.

Gene transfer of tissue inhibitor of metalloproteinases-3 reverses the inhibitory effects of TNF-alpha on Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts.

Drynda A, Quax PH, Neumann M, van der Laan WH, Pap G, Drynda S, Meinecke I, Kekow J, Neumann W, Huizinga TW, Naumann M, König W, Pap T.

J Immunol. 2005 May 15;174(10):6524-31.

16.

No therapeutic effect of plasmin antagonist tranexamic acid in rheumatoid arthritis. A double-blind placebo-controlled pilot study.

van der Laan WH, Ronday HK, TeKoppele JM, Breedveld FC, Huizinga TW, Verheijen JH.

Clin Exp Rheumatol. 2003 May-Jun;21(3):359-62.

PMID:
12846058
17.

Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3.

van der Laan WH, Quax PH, Seemayer CA, Huisman LG, Pieterman EJ, Grimbergen JM, Verheijen JH, Breedveld FC, Gay RE, Gay S, Huizinga TW, Pap T.

Gene Ther. 2003 Feb;10(3):234-42.

PMID:
12571631
18.

Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10.

Tolboom TC, Pieterman E, van der Laan WH, Toes RE, Huidekoper AL, Nelissen RG, Breedveld FC, Huizinga TW.

Ann Rheum Dis. 2002 Nov;61(11):975-80.

19.

Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone.

Verhoeven AC, Boers M, te Koppele JM, van der Laan WH, Markusse HM, Geusens P, van der Linden S.

Rheumatology (Oxford). 2001 Nov;40(11):1231-7.

PMID:
11709606
20.

Reliability of spot samples for assessment of urinary excretion of pyridinoline in patients with rheumatoid arthritis.

Verhoeven AC, Boers M, te Koppele JM, van der Laan WH, de Roos J, van der Linden S.

Clin Exp Rheumatol. 2001 Jan-Feb;19(1):78-80.

PMID:
11247330

Supplemental Content

Loading ...
Support Center